What does Inwendige Ziekten Sint-Trudo do?

Inwendige Ziekten Sint-Trudo is a specialist medical practice in Sint-Truiden. Private Limited, started on 6 August 2018, 1 establishment.

What is the address of Inwendige Ziekten Sint-Trudo?

The registered office of Inwendige Ziekten Sint-Trudo is located at Diestersteenweg 100, 3800 Sint-Truiden.

Is Inwendige Ziekten Sint-Trudo still active?

Yes. According to the CBE (16 September 2026) Inwendige Ziekten Sint-Trudo is active, legal situation “Normale toestand”, started on 6 August 2018.

Is Inwendige Ziekten Sint-Trudo registered on Peppol?

Yes, Inwendige Ziekten Sint-Trudo is registered on the Peppol network with ID 0208:0700681973.

What is the enterprise number of Inwendige Ziekten Sint-Trudo?

The enterprise number of Inwendige Ziekten Sint-Trudo is BE0700681973.

When was Inwendige Ziekten Sint-Trudo founded?

Inwendige Ziekten Sint-Trudo was founded on 6 August 2018.

Is Inwendige Ziekten Sint-Trudo a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 6 August 2018; 5 annual accounts filed, latest fiscal year 2025; 11 directors known from the annual account.

How much profit did Inwendige Ziekten Sint-Trudo make in 2025?

Inwendige Ziekten Sint-Trudo recorded a loss after taxes of € 644 in financial year 2025.

What is the revenue of Inwendige Ziekten Sint-Trudo?

As a small company, Inwendige Ziekten Sint-Trudo is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 20,588.

Inwendige Ziekten Sint-Trudo (Private Limited)

Q: Who are the directors of Inwendige Ziekten Sint-Trudo?

According to the 2025 annual accounts, the directors of Inwendige Ziekten Sint-Trudo are: Dokter Veronique Bulens Geriatrie BV, Dr. Charlotte Debergh BV, Dr. Joosen Henk BV, Dokter Elke Van Mieghem BV, Dr. Verheezen Jolanda BV, Dr. L. Van Den Bergh BV, Dr. Nijs Jochen BV, Dr. Elien Dewaele BV.

Dossier Inwendige Ziekten Sint-Trudo, printed on 16 September 2026 from databakkes.be/en/0700681973/inwendige-ziekten-sint-trudo. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Busy address KBO

17 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

Inwendige Ziekten Sint-Trudo from Sint-Truiden, company number BE0700681973, closed financial year 2025 with a result of € -644 after tax. For that financial year Inwendige Ziekten Sint-Trudo recorded a gross margin of € 20,588 and equity of € 20,108. Compared with financial year 2024, the result moved from € 549 to € -644. The company made a loss. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 30, 2026.

What it is worth Healthy

€ 20,108

▼ 3% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -644

▼ still € 549 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 42,151

▲ 274% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 108.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 37,684

▼ 25% vs 2024

€ 13,196 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 55,532

▼ 60% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 12,067 Gross margin 2022: € 12,067 First fiscal year in the series	€ 7,408 Gross margin 2023: € 7,408 ▼ 39% vs 2022 (€ 12,067) Unfavourable step	€ 18,530 Gross margin 2024: € 18,530 ▲ 150% vs 2023 (€ 7,408) Favourable step	€ 20,588 Gross margin 2025: € 20,588 ▲ 11% vs 2024 (€ 18,530) Favourable step	▲ 11%
Profit after taxes	€ -1 Profit after taxes 2022: € -1 First fiscal year in the series	€ 2 Profit after taxes 2023: € 2 ▲ € 4 vs 2022 (€ -1) Favourable step	€ 549 Profit after taxes 2024: € 549 ▲ € 546 vs 2023 (€ 2) Favourable step	€ -644 Profit after taxes 2025: € -644 ▼ € 1,192 vs 2024 (€ 549) Unfavourable step	▼ € 1,192
Equity	€ 20,200 Equity 2022: € 20,200 First fiscal year in the series	€ 20,203 Equity 2023: € 20,203 Unchanged (€ 20,200) Favourable step	€ 20,751 Equity 2024: € 20,751 ▲ 3% vs 2023 (€ 20,203) Favourable step	€ 20,108 Equity 2025: € 20,108 ▼ 3% vs 2024 (€ 20,751) Unfavourable step	▼ 3%
Total debts	€ 834,565 Total debts 2022: € 834,565 First fiscal year in the series	€ 1,057,441 Total debts 2023: € 1,057,441 ▲ 27% vs 2022 (€ 834,565) Unfavourable step	€ 1,081,323 Total debts 2024: € 1,081,323 ▲ 2% vs 2023 (€ 1,057,441) Unfavourable step	€ 1,273,639 Total debts 2025: € 1,273,639 ▲ 18% vs 2024 (€ 1,081,323) Unfavourable step	▲ 18%
Cash	€ 7,672 Cash 2022: € 7,672 First fiscal year in the series	€ 37,926 Cash 2023: € 37,926 ▲ € 30,254 vs 2022 (€ 7,672) Favourable step	€ 11,256 Cash 2024: € 11,256 ▼ 70% vs 2023 (€ 37,926) Unfavourable step	€ 42,151 Cash 2025: € 42,151 ▲ 274% vs 2024 (€ 11,256) Favourable step	▲ 274%
Retained profit	€ 200 Retained profit 2022: € 200 First fiscal year in the series	€ 203 Retained profit 2023: € 203 ▲ 1% vs 2022 (€ 200) Favourable step	€ 751 Retained profit 2024: € 751 ▲ 271% vs 2023 (€ 203) Favourable step	€ 108 Retained profit 2025: € 108 ▼ 86% vs 2024 (€ 751) Unfavourable step	▼ 86%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 62,443 Bank debt 2023: € 62,443 Unchanged (€ 0) Unfavourable step	€ 50,330 Bank debt 2024: € 50,330 ▼ 19% vs 2023 (€ 62,443) Favourable step	€ 37,684 Bank debt 2025: € 37,684 ▼ 25% vs 2024 (€ 50,330) Favourable step	▼ 25%
Balance sheet total	€ 854,765 Balance sheet total 2022: € 854,765 First fiscal year in the series	€ 1,077,644 Balance sheet total 2023: € 1,077,644 ▲ 26% vs 2022 (€ 854,765) Unchanged	€ 1,102,074 Balance sheet total 2024: € 1,102,074 ▲ 2% vs 2023 (€ 1,077,644) Unchanged	€ 1,293,747 Balance sheet total 2025: € 1,293,747 ▲ 17% vs 2024 (€ 1,102,074) Unchanged	▲ 17%

Key figures of Inwendige Ziekten Sint-Trudo, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Inwendige Ziekten Sint-Trudo?

What happened at Inwendige Ziekten Sint-Trudo in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 30, 2026 New annual accounts for financial year 2025: loss of € 644 (▼ € 1,192 vs 2024). Source: NBB ↗
2025 Dr. Charlotte Debergh BV became a director. NBB
2025 Robert De Smet Geriatrie BV became a director. NBB
2020 Dokter Veronique Bulens Geriatrie BV became a director. NBB
2020 Dr. Elien Dewaele BV became a director. NBB
Aug 6, 2018 New establishment in Sint-Truiden. KBO
Aug 6, 2018 Start of the company according to the CBE. KBO
2018 Dr. Joosen Henk BV became a director. NBB

In short

From € 1 loss in 2022 to € 644 loss in 2025.

Paid € 9,232 in corporate taxes since 2022.

Best year ever: 2024, with € 549 profit.

Original PDFs at the National Bank ↗

A new publication or filing at Inwendige Ziekten Sint-Trudo? We notify you, reason included.

Follow Inwendige Ziekten Sint-Trudo

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Dr. Charlotte Debergh 11.1%

Dr. L. VAN DEN BERGH 7.2%

Dr. JOOSEN Henk 7.2%

DR. NIJS JOCHEN 7.2%

The stake of Dr. Charlotte Debergh, Dr. L. VAN DEN BERGH, Dr. JOOSEN Henk, DR. NIJS JOCHEN, Dr. Verheezen Jolanda, Dr. K. Gysen, Dokter Elke Van Mieghem, Oncologie, Dr. Elien Dewaele comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Inwendige Ziekten Sint-Trudo

Behind Inwendige Ziekten Sint-Trudo are Dokter Veronique Bulens Geriatrie BV, Dr. Charlotte Debergh BV, Dr. Joosen Henk BV, Dokter Elke Van Mieghem BV, Dr. Verheezen Jolanda BV and Dr. L. Van Den Bergh BV. The shares are held by Dr. Charlotte Debergh (11.1%), Dr. L. VAN DEN BERGH (7.2%), Dr. JOOSEN Henk (7.2%), DR. NIJS JOCHEN (7.2%), Dr. Verheezen Jolanda (7.2%) and Dr. K. Gysen (7.1%).

See the full network in the app